Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.

María González Cao,Susana Puig,Josep Malvehy,Josep Eugeni Herrero,Rosa M. Martí,Carlos Conill,Marcelo Sánchez,Begoña Mellado,Pere Gascón,Teresa Castel

Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.

2005

María González Cao
Susana Puig
Josep Malvehy
Josep Eugeni Herrero
Rosa M. Martí
Carlos Conill
Marcelo Sánchez
Begoña Mellado
Pere Gascón
Teresa Castel

Introduction Metastatic melanoma has an ominous prognosis. Bio-chemotherapy regimens can increase the response rate but with a high degree of toxicity due, mainly, to the use of high-dose intravenous interleukin-2.

Keywords:

General surgery
Pathology
Melanoma
Interleukin 2
Dacarbazine
Medicine
metastatic melanoma
Toxicity
low doses
chemo immunotherapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations